BACKGROUND: Serotonin transporters (SERT) are a major target for antidepressant medication, although there have been limited in vivo studies of SERT availability in patients being treated with antidepressants. It is not known whether SERT availability differs in treatment-responsive and -nonresponsive patients receiving long-term treatment. In this study, we used single photon emission computed tomography (SPECT) to compare SERT residual availability in unipolar responders and nonresponders during long-term antidepressant treatment. Dopamine transporter (DAT) availability was also assessed in the same patients to examine the relationship between the two transporter systems. METHODS: Twenty-four medicated unipolar patients were recruited, of whom 11 were responders and 13 were nonresponders. All patients underwent SPECT with [123I] beta-carbomethoxy-3-beta-(4 iodophenyl)tropane. Brain SERT was measured in the brain stem and diencephalon, and DAT was measured in the striatum. Residual availability was calculated as a ratio of specific to nonspecific uptake, with the occipital region used as the nonspecific reference region. RESULTS: There was no difference between responders and nonresponders in SERT availability. Dopamine transporter availability was similar in responders and nonresponders, and there was no association between SERT and DAT availability. CONCLUSIONS: Serotonin transporter availability does not discriminate responders and nonresponders during long-term treatment with antidepressants.
BACKGROUND:Serotonin transporters (SERT) are a major target for antidepressant medication, although there have been limited in vivo studies of SERT availability in patients being treated with antidepressants. It is not known whether SERT availability differs in treatment-responsive and -nonresponsive patients receiving long-term treatment. In this study, we used single photon emission computed tomography (SPECT) to compare SERT residual availability in unipolar responders and nonresponders during long-term antidepressant treatment. Dopamine transporter (DAT) availability was also assessed in the same patients to examine the relationship between the two transporter systems. METHODS: Twenty-four medicated unipolar patients were recruited, of whom 11 were responders and 13 were nonresponders. All patients underwent SPECT with [123I] beta-carbomethoxy-3-beta-(4 iodophenyl)tropane. Brain SERT was measured in the brain stem and diencephalon, and DAT was measured in the striatum. Residual availability was calculated as a ratio of specific to nonspecific uptake, with the occipital region used as the nonspecific reference region. RESULTS: There was no difference between responders and nonresponders in SERT availability. Dopamine transporter availability was similar in responders and nonresponders, and there was no association between SERT and DAT availability. CONCLUSIONS:Serotonin transporter availability does not discriminate responders and nonresponders during long-term treatment with antidepressants.
Authors: Alice Nicol; Rajeev Krishnadas; Sue Champion; Gilles Tamagnan; Jeffrey S Stehouwer; Mark M Goodman; Donald M Hadley; Sally L Pimlott Journal: Eur J Nucl Med Mol Imaging Date: 2012-05 Impact factor: 9.236
Authors: Ana M Catafau; Victor Perez; Pedro Plaza; Juan-Carlos Pascual; Santiago Bullich; Marina Suarez; Maria M Penengo; Iluminada Corripio; Dolors Puigdemont; Monica Danus; Javier Perich; Enric Alvarez Journal: Psychopharmacology (Berl) Date: 2006-10-11 Impact factor: 4.530
Authors: Olof R Hjorth; Andreas Frick; Malin Gingnell; Johanna M Hoppe; Vanda Faria; Sara Hultberg; Iman Alaie; Kristoffer N T Månsson; Jörgen Rosén; Margareta Reis; Kurt Wahlstedt; My Jonasson; Mark Lubberink; Gunnar Antoni; Mats Fredrikson; Tomas Furmark Journal: Transl Psychiatry Date: 2021-11-03 Impact factor: 6.222
Authors: Olof Hjorth; Andreas Frick; Malin Gingnell; Jonas Engman; Johannes Björkstrand; Vanda Faria; Iman Alaie; Per Carlbring; Gerhard Andersson; My Jonasson; Mark Lubberink; Gunnar Antoni; Margareta Reis; Kurt Wahlstedt; Mats Fredrikson; Tomas Furmark Journal: Transl Psychiatry Date: 2022-10-07 Impact factor: 7.989